Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Breast Neoplasms
/ drug therapy
Bridged-Ring Compounds
Female
Humans
Receptor, ErbB-2
/ genetics
Retrospective Studies
Taxoids
/ therapeutic use
Trastuzumab
/ therapeutic use
Vinorelbine
/ therapeutic use
Breast cancer
HER-2 positive
Metastatic
Pertuzumab
Taxane
Trastuzumab
Vinorelbine
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
15
01
2021
accepted:
16
03
2021
pubmed:
28
3
2021
medline:
9
7
2021
entrez:
27
3
2021
Statut:
ppublish
Résumé
The combination of a taxane with trastuzumab and pertuzumab is standard of care for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The combination of vinorelbine with trastuzumab and pertuzumab showed anti-tumor activity in a phase 2 trial. The databases of two tertiary medical centers were retrospectively searched for patients with HER2-positive metastatic breast cancer who underwent first-line treatment in 2013-2019 with a taxane or vinorelbine in combination with trastuzumab and pertuzumab. Groups were compared for progression-free survival (PFS), overall survival (OS), and toxicity profile. The study included 87 patients in the taxane group and 65 in the vinorelbine group. Overall median PFS was significantly longer in the taxane group [HR 0.56 (0.36-0.88), P = 0.01], but on multivariate analysis the difference was not statistically significant [HR 0.68 (0.4-1.1, P = 0.11)]. PFS was comparable in both groups of patients with recurrent disease [HR 0.94 (0.5-1.79), P = 0.85]. However, in patients with de novo metastatic disease, the difference in favor of the taxane group was pronounced [HR 0.4 (0.2-0.78), P = 0.007] and maintained significance on multivariate analysis [HR 0.46 (0.2-0.97, P = 0.04)]. There was no statistical significant difference in OS in the whole cohort [HR 0.69 (0.39-1.23)] or the subgroups. Patients with HER2-positive metastatic breast cancer had similar survival with first-line treatment of taxane or vinorelbine combined with trastuzumab and pertuzumab. When the analysis was adjusted for prognostic factors, there was no PFS benefit for taxanes except in the subgroup with de novo disease.
Sections du résumé
BACKGROUND
BACKGROUND
The combination of a taxane with trastuzumab and pertuzumab is standard of care for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The combination of vinorelbine with trastuzumab and pertuzumab showed anti-tumor activity in a phase 2 trial.
PATIENTS AND METHODS
METHODS
The databases of two tertiary medical centers were retrospectively searched for patients with HER2-positive metastatic breast cancer who underwent first-line treatment in 2013-2019 with a taxane or vinorelbine in combination with trastuzumab and pertuzumab. Groups were compared for progression-free survival (PFS), overall survival (OS), and toxicity profile.
RESULTS
RESULTS
The study included 87 patients in the taxane group and 65 in the vinorelbine group. Overall median PFS was significantly longer in the taxane group [HR 0.56 (0.36-0.88), P = 0.01], but on multivariate analysis the difference was not statistically significant [HR 0.68 (0.4-1.1, P = 0.11)]. PFS was comparable in both groups of patients with recurrent disease [HR 0.94 (0.5-1.79), P = 0.85]. However, in patients with de novo metastatic disease, the difference in favor of the taxane group was pronounced [HR 0.4 (0.2-0.78), P = 0.007] and maintained significance on multivariate analysis [HR 0.46 (0.2-0.97, P = 0.04)]. There was no statistical significant difference in OS in the whole cohort [HR 0.69 (0.39-1.23)] or the subgroups.
CONCLUSIONS
CONCLUSIONS
Patients with HER2-positive metastatic breast cancer had similar survival with first-line treatment of taxane or vinorelbine combined with trastuzumab and pertuzumab. When the analysis was adjusted for prognostic factors, there was no PFS benefit for taxanes except in the subgroup with de novo disease.
Identifiants
pubmed: 33772709
doi: 10.1007/s10549-021-06198-4
pii: 10.1007/s10549-021-06198-4
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Bridged-Ring Compounds
0
Taxoids
0
taxane
1605-68-1
Receptor, ErbB-2
EC 2.7.10.1
pertuzumab
K16AIQ8CTM
Trastuzumab
P188ANX8CK
Vinorelbine
Q6C979R91Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-387Références
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551
doi: 10.3322/caac.21551
pubmed: 30620402
Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju055
doi: 10.1093/jnci/dju055
pubmed: 24777111
pmcid: 4580552
Ross JS, Slodkowska EA, Symmans WF et al (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368. https://doi.org/10.1634/theoncologist.2008-0230
doi: 10.1634/theoncologist.2008-0230
pubmed: 19346299
Gradishar WJ, Abraham J, Aft R et al (2019) NCCN Guidelines Version 1.2019 Breast Cancer NCCN Guidelines
Swain SM, Baselga J, Kim S-B et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724–734. https://doi.org/10.1056/NEJMoa1413513
doi: 10.1056/NEJMoa1413513
pubmed: 25693012
pmcid: 5584549
Baselga J, Cortés J, Kim S-B et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1113216
doi: 10.1056/NEJMoa1113216
pubmed: 23020162
pmcid: 5125250
Bachelot T, Ciruelos E, Schneeweiss A et al (2019) Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol 30:766–773. https://doi.org/10.1093/annonc/mdz061
doi: 10.1093/annonc/mdz061
pubmed: 30796821
Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2–positive breast cancer: the HERNATA study. J Clin Oncol 29:264–271. https://doi.org/10.1200/JCO.2010.30.8213
doi: 10.1200/JCO.2010.30.8213
pubmed: 21149659
Eisenhauer EA, Therasse P, Bogaerts J, et al (2008) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). https://doi.org/10.1016/j.ejca.2008.10.026
Cancer Institute N (2017) Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Shimozuma K, Ohashi Y, Takeuchi A et al (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 20:3355–3364. https://doi.org/10.1007/s00520-012-1492-x
doi: 10.1007/s00520-012-1492-x
pubmed: 22584733
Rivera E, Cianfrocca M (2015) Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 75:659–670. https://doi.org/10.1007/s00280-014-2607-5
doi: 10.1007/s00280-014-2607-5
pubmed: 25596818
pmcid: 4365177
Marty M, Fumoleau P, Adenis A et al (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643–1649. https://doi.org/10.1023/A:1013180903805
doi: 10.1023/A:1013180903805
pubmed: 11822766
Bourgeois H, Vermorken J, Dark G et al (2007) Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemother Pharmacol 60:407–413. https://doi.org/10.1007/s00280-007-0510-z
doi: 10.1007/s00280-007-0510-z
pubmed: 17541591
Variol P, Nguyen L, Tranchand B, Puozzo C (2002) A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 58:467–476. https://doi.org/10.1007/s00228-002-0506-x
doi: 10.1007/s00228-002-0506-x
pubmed: 12389069
Aapro M, Finek J (2012) Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev 38:120–126
doi: 10.1016/j.ctrv.2011.05.005
Perez EA, López-Vega JM, Petit T et al (2016) Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res 18:126. https://doi.org/10.1186/s13058-016-0773-6
doi: 10.1186/s13058-016-0773-6
pubmed: 27955684
pmcid: 5154110
Andersson M, López-Vega JM, Petit T et al (2017) Efficacy and safety of pertuzumab and trastuzumab administered in a single infusion bag, followed by vinorelbine: VELVET cohort 2 final results. Oncologist 22:1160–1168. https://doi.org/10.1634/theoncologist.2017-0079
doi: 10.1634/theoncologist.2017-0079
pubmed: 28592618
pmcid: 5634765
Christensen T, Berg T, Nielsen LB et al (2020) Dual HER2 blockade in the first-line treatment of metastatic breast cancer—a retrospective population-based observational study in Danish patients. Breast 51:34–39. https://doi.org/10.1016/j.breast.2020.03.002
doi: 10.1016/j.breast.2020.03.002
pubmed: 32200206
pmcid: 7375653
Robert NJ, Goertz H-P, Chopra P et al (2017) HER2-positive metastatic breast cancer patients receiving pertuzumab in a community oncology practice setting: treatment patterns and outcomes. Drugs Real World Outcomes 4:1–7. https://doi.org/10.1007/s40801-016-0102-5
doi: 10.1007/s40801-016-0102-5
pubmed: 28063028
pmcid: 5332306
De Placido S, Giuliano M, Schettini F et al (2018) Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast 38:86–91. https://doi.org/10.1016/j.breast.2017.12.012
doi: 10.1016/j.breast.2017.12.012
pubmed: 29287189
Gamucci T, Pizzuti L, Natoli C et al (2019) A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study Cancer Biol Ther 20:192–200. https://doi.org/10.1080/15384047.2018.1523095
doi: 10.1080/15384047.2018.1523095
pubmed: 30403909
Tripathy D, Brufsky A, Cobleigh M et al (2020) De novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry. Oncologist 25:e214–e222. https://doi.org/10.1634/theoncologist.2019-0446
doi: 10.1634/theoncologist.2019-0446
pubmed: 32043771